Effects of Prostaglandin Analogue Washout Following Long-term Therapy in Adults With Primary Open Angle Glaucoma
Primary Open-Angle Glaucoma, Mild Stage, Glaucoma, Suspect, Ocular Hypertension
About this trial
This is an interventional treatment trial for Primary Open-Angle Glaucoma, Mild Stage focused on measuring anti-glaucoma medications, glaucoma, prostaglandin analogues, medication washout
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of glaucoma or or ocular hypertension
- Prostaglandin analogue responder >20% intraocular pressure (IOP) reduction from baseline
- Age >18 years
- Baseline IOP (pre-treatment) ≥21 mmHg
- Prostaglandin analogue treatment duration > 6 months
Exclusion Criteria:
- Diagnosis of acute angle closure glaucoma
- Treatment with > 1 glaucoma medication
- Topical steroid > 3 consecutive weeks
- Intraocular surgery in last 6 months prior to enrollment
- Glaucoma laser intervention in last 12 months prior to enrollment
- Best Corrected Visual Acuity (BCVA) < 70 letters (EDTRS or Snellen equivalent)
- Visual field mean deviation <-3
Sites / Locations
- Ivey Eye Institute
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Washout
Control
Discontinuation of topical prostaglandin analogue therapy: Participants are asked to discontinue (washout) their prostaglandin analogue for 42 days. As the experimental group, the purpose of this arm is to determine the lingering IOP-reducing effects following discontinuation of chronic prostaglandin analogue therapy, and to determine if IOP rises back to baseline (pre-treatment values).
Patients are asked to remain on their prostaglandin analogues and continue treatment as prescribed by their ophthalmologist. The purpose of this arm is to minimize bias in intraocular pressure readings.